[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-351365-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-351365-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","roles-of-adp-ribosyltransferases-in-cancer-review","Roles of ADP-Ribosyltransferases in Cancer - Review","","ADP-ribosyltransferases (ARTs) govern critical cancer processes, including DNA repair, transcriptional regulation, immune signaling, and resistance to therapy. The clostridial toxin-like ARTC family and the diphtheria toxin-like ARTD family contribute to genomic stability through mono(ADP-ribosyl)ation (MARylation) and poly(ADP-ribosyl)ation (PARylation). The review surveys literature from 1992–2025, highlighting ARTC and ARTD roles and summarizing current knowledge on specific inhibitors, including PARP-targeted strategies and limitations of ART-selective inhibitor development.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/roles-of-adp-ribosyltransferases-in-cancer-review/351365/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/roles-of-adp-ribosyltransferases-in-cancer-review/351365.png","ImageObject",300,407,{"name":42,"@type":43},"WPS_1786070896","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What biological roles do ADP-ribosyltransferases (ARTs) play in cancer?","Question",{"text":63,"@type":64},"ARTs regulate DNA repair, transcription, immune responses, and contribute to treatment resistance. They support genomic stability through MARylation or PARylation of proteins.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do the ARTC and ARTD families differ in their ADP-ribosylation activities?",{"text":68,"@type":64},"The ARTC family consists of clostridial toxin-like enzymes with human members that act as mono-ADP-ribosyltransferases or inactive proteins, often as extracellular or membrane-bound/secreted proteins. The ARTD family includes multiple proteins functioning as poly-ADP-ribosyltransferases, mono-ADP-ribosyltransferases, or inactive enzymes, with key motif variations linked to activity.",{"name":70,"@type":61,"acceptedAnswer":71},"Why are PARP inhibitors clinically important for certain cancers?",{"text":72,"@type":64},"PARP1 and PARP2 are activated by DNA single-strand breaks and are validated targets in cancers with homologous recombination deficiency, such as BRCA1/2-mutated breast cancer. Their inhibition can create synthetic lethality and show clinical efficacy.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},351365,1790854668,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},549768072016,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Tech Science Press  \n[https://doi. org/10.32604/or.2026.072194](https://doi. org/10.32604/or.2026.072194)  \nREVIEW  \nRoles of ADP-Ribosyltransferases in Cancer  \nMaureen Veilleux1,2,\\#, Anh Nguyen3,\\#, Charles Cao4,\\# and Yihui Shi2, *  \n1 Institute of Pharmaceutical and Biological Sciences, Université Claude Bernard Lyon 1, Lyon, France 2 California Pacific Medical Center Research Institute, Sutter Health, San Francisco, CA, USA 3 College of Medicine, California Northstate University, Elk Grove, CA, USA  \n4 Rollins School of Public Health, Emory University, Atlanta, GA, USA  \n*[Corresponding Author: Yihui Shi. Email: yihui.shi@sutterhealth.org](Corresponding Author: Yihui Shi. Email: yihui.shi@sutterhealth.org)  \n\\# These authors contributed equally to this work  \nReceived: 21 August 2025; Accepted: 15 January 2026; Published: 23 March 2026  \nABSTRACT: ADP-ribosyltransferases (ARTs) regulate key processes in cancer, including DNA repair, transcription, immune responses, and treatment resistance. The clostridial toxin-like ADP-ribosyltransferase (ARTC) family and the diphtheria toxin-like ADP-ribosyltransferase (ARTD) family play a crucial role in genomic stability by modification of proteins either with mono(ADP-ribosyl)ation (MARylation) or poly(ADP-ribosyl)ation (PARylation) . These ARTs are promising therapeutic targets and could serve as biomarkers in cancer management. This review explores the roles of these enzymes and current knowledge on specific inhibitors. A literature search was conducted in PubMed and Google Scholar to identify studies published between 1992 and 2025 on ADP-ribosyltransferases and their roles in cancer. Among ARTC family, ART1 and ART3 modulate the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) pathway, influencing angiogenesis, tumor growth, and immune evasion via cluster of differentiation 8+ (CD8+) T-cell apoptosis. Within the ARTD family, poly(ADP-ribose)polymerase (PARP)1 and PARP2 are activated by DNA single-strand breaks and are clinically validated targets in cancers with homologous recombination deficiency, such as breast cancer susceptibility genes 1/2 (BRCA1/2)-mutated breast cancer. Their inhibition exemplifies synthetic lethality and has shown clinical efficacy. Four PARP inhibitors, olaparib, niraparib, rucaparib, are approved by the Food and Drug Administration (FDA) approved. Despite these advances, selective inhibitors for ARTs remain underexplored. Ongoing research focuses on overcoming PARP inhibitor resistance, improving biomarker-driven patient selection, and expanding therapeutic strategies that target ART-related pathways.  \nKEYWORDS: Cancer therapeutics; gene targets; synthetic lethality; ADP-ribosyltransferases (ARTs); poly(ADPribose)polymerase (PARPs)  \n1 Introduction  \nADP-ribosyltransferases (ARTs) utilize a NAD+-dependent modification to alter protein functions. The two main forms of these modification processes are mono-ADP-ribosylation (MARylation) and poly-ADP-ribosylation (PARylation) . MARylation is still understudied, but there is a greater number of mono(ADP-ribosyl)transferases than poly(ADP-ribosyl)transferases. Current research points to MARylation as being capable of modifying a variety of amino acid residues, while PARylation mostly modifies serine residues. Thus, MARylation can potentially play roles in several biological processes, including DNA damage repair and inflammatory responses [1] . The function of PARylation in DNA damage repair pathways and its role with ubiquitination of PARylated proteins has been well-studied [2] . There are two  \nCopyright © 2026 The Authors. Published by Tech Science Press. This work is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.  \nmajor enzyme families capable of producing ADP-ribosylated proteins. The first is the clostridial toxin-like ADP-ribosyltransferase (A","cbCaiqJkNNM3h7VF","https://ap.wps.com/l/cbCaiqJkNNM3h7VF","pdf",4635100,26,"English","# Abstract\n# Introduction\n## ADP-ribosyltransferase modification types\n## ARTC and ARTD enzyme families\n## PARP inhibition and cancer therapy implications\n# Table 1: Mammalian ADP-Ribosyltransferase enzymes","[{\"question\":\"What biological roles do ADP-ribosyltransferases (ARTs) play in cancer?\",\"answer\":\"ARTs regulate DNA repair, transcription, immune responses, and contribute to treatment resistance. They support genomic stability through MARylation or PARylation of proteins.\"},{\"question\":\"How do the ARTC and ARTD families differ in their ADP-ribosylation activities?\",\"answer\":\"The ARTC family consists of clostridial toxin-like enzymes with human members that act as mono-ADP-ribosyltransferases or inactive proteins, often as extracellular or membrane-bound/secreted proteins. The ARTD family includes multiple proteins functioning as poly-ADP-ribosyltransferases, mono-ADP-ribosyltransferases, or inactive enzymes, with key motif variations linked to activity.\"},{\"question\":\"Why are PARP inhibitors clinically important for certain cancers?\",\"answer\":\"PARP1 and PARP2 are activated by DNA single-strand breaks and are validated targets in cancers with homologous recombination deficiency, such as BRCA1/2-mutated breast cancer. Their inhibition can create synthetic lethality and show clinical efficacy.\"}]","Roles of ADP-Ribosyltransferases in Cancer - Review | PDF",1790093740,66,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a6bfeb72b1857c41c86e7493685a4b26.webp",983,1271,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d54f700a1bc49eb3c62367fa2812e545.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ce7133c8c224a9004c951dfc6c5304ec.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d1b820abc5500b0d4f32315c396c7bbf.webp",980,1267]